Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OvaRex PK and Safety in Ovarian Cancer
NCT00034138Phase 2Terminated
- Sponsor
- Unither Pharmaceuticals
- Start
- Mar 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of oregovomab in ovarian epithelial carcinoma, sponsored by Unither Pharmaceuticals. Started Mar 2002; status: terminated.
02
Drugs
oregovomab
03
Conditions
ovarian epithelial carcinoma
Beyond the preview
Go deeper on NCT00034138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034138.